Deregulated nutrient sensing

Your cells run four molecular "fuel gauges" that read how much food is around and decide whether to grow and store or to repair and recycle — and with age that decision gets stuck on "grow." The honest lesson from recent human work is balance rather than maximal suppression: the goal is to restore the youthful oscillation between feeding and fasting, not to starve the growth machinery into the ground.

Deregulated nutrient sensing is the sixth of the twelve hallmarks of aging and arguably the most central — it is the hub where diet meets the rate of biological aging. The cell constantly measures the availability of energy and nutrients and uses that reading to balance anabolism (building and storing) against catabolism (breaking down and repairing).^[1] The governing principle of geroscience here is blunt: sustained activation of the pro-growth pathways accelerates aging, while activation of the pro-repair, stress-response pathways promotes longevity.^[2] Most of the interventions on this site work, in part, by tilting that balance back toward repair. This is the most heavily targeted hallmark in all of longevity science.

How confident should you be

Descriptive — Strong. Intervention — Strong in animals, Weak-to-Moderate in humans, and on biomarkers rather than survival.

The mechanism is as well established as anything in aging biology: the four pathways exist, they respond to food, and turning the growth side down lengthens life in worms, flies and mice with a reproducibility almost nothing else in the field matches. The gap opens at the species boundary. No trial has tested any of these levers against human mortality, and only one has tested a clinical endpoint at all — a six-week course of mTOR inhibitors that cut infection rates over the following year, a short trial with a narrow endpoint. Everything else is a biomarker: a two-year calorie-restriction trial that moved one biological-age clock by a few percent, a fasting-mimicking result from a post-hoc analysis, and a rapamycin trial that missed what it set out to measure. The drugs section is the weakest part of this page for a reason.

The four fuel gauges

Strong. The four-sensor architecture and its wiring are settled cell biology, mapped in detail across species.

Nutrient sensing runs on four interconnected molecular networks, which split cleanly into an accelerator pair and a brake pair.^[3]

The accelerators (pro-growth, pro-aging):

Insulin and insulin-like growth factor 1 (IGF-1) signalling, usually shortened to IIS, is the most evolutionarily conserved aging-control pathway, present from worms to humans. It responds mainly to carbohydrate intake: insulin or IGF-1 binds its receptor and triggers a kinase cascade that drives growth and storage. A key step is shoving the forkhead box O (FOXO) transcription factors out of the cell nucleus — and since FOXO switches on genes for stress resistance and autophagy, keeping it out suppresses the cell's own longevity program.^[4]
mTOR (mechanistic target of rapamycin) is the master growth hub, integrating signals from amino acids and growth factors to ramp up protein and fat synthesis while shutting down recycling.^[5]

The brakes (pro-repair, pro-longevity):

AMPK (AMP-activated protein kinase) is the low-fuel sensor: when energy runs low it activates, switches on catabolic energy-producing pathways, inhibits mTOR, and triggers autophagy and the building of new mitochondria.^[6]
Sirtuins, a family of seven repair enzymes, depend for their activity on NAD⁺ (nicotinamide adenine dinucleotide), a molecule that declines with age — which is what links their function directly to the cell's metabolic state and to mitochondrial health.^[7]

Metabolic overdrive: when the oscillation flattens

Strong for the cellular mechanism; Moderate for the claim that this is what drives human aging. The oscillator has been mapped in cells and animals; that its flattening is what ages people is inference, not measurement.

In youth these four sensors form an adaptive oscillator. After eating, the accelerators (IIS, mTOR) switch on for growth and repair; during fasting, the brakes (AMPK, sirtuins) take over, inhibiting mTOR, raising NAD⁺, and driving autophagy and mitochondrial renewal. Health depends on the swing between the two states.^[8]

With age — and with constant grazing on a modern diet — that oscillation flattens into a state of chronic metabolic overdrive: IIS and mTOR idle high, AMPK and sirtuin activity fall, and the cell is locked in grow-and-store mode with the repair program switched off.^[9] Two things accelerate the decline of the brake side. NAD⁺ — the fuel sirtuins need — is progressively consumed by a DNA-repair enzyme responding to accumulating damage and by an inflammation-driven enzyme on the surface of immune cells, so sirtuin activity is starved just when it is needed.^[10] And persistent mTOR activity suppresses autophagy, letting damaged components and leaked mitochondrial DNA accumulate, which inflames tissue and further deafens cells to insulin — a self-reinforcing loop that ties nutrient sensing directly to inflammaging.^[11]

Insulin: the part of this you can actually measure

Moderate. That chronic high insulin marks the problem is well supported; the thresholds used to interpret it come from cohort data rather than trials, and live under midlife labs.

Most of this hallmark is invisible from the outside. One arm of it is not. As insulin clearance falls with age, the body compensates by running chronically high insulin, which keeps the IIS accelerator pressed and suppresses the FOXO stress-response program — the whole-body version of what the cell-level picture describes.^[12] That shows up on a blood test years before fasting glucose or the three-month average blood-sugar marker (HbA1c) move, which is why fasting insulin — and the HOMA-IR score calculated from fasting insulin and glucose together — is the one routine measurement that reads this hallmark directly. See metabolic flexibility for the physiology of losing and regaining the feed–fast swing.

The growth-signalling paradox: less is more, but not zero

Strong in animals; Weak for the human U-shape — inferred from animal work and from observational associations between IGF-1 levels and mortality, not from any trial.

The most counterintuitive finding in this field is that dialling down the body's main growth signal extends lifespan. Mutations that reduce insulin/IGF-1 or mTOR signalling are among the most reproducible longevity levers in biology, lengthening life across worms, flies, and mice.^[13]

But the relationship is a U-shape, not a straight line, and this is the crucial calibration. Too much growth signalling feeds cancer and metabolic disease; too little brings frailty, muscle loss, and impaired immunity. The goal is to restore the youthful swing between growth and repair — not to abolish growth — a theme that recurs every time these two forces are in tension.^[14]

mTOR: the central hub and the protein question

Strong for the mechanism; Weak for any single amino acid as a practical lever.

Of the four, mTOR is the most directly actionable. It operates as two complexes — mTOR complex 1 (mTORC1), the well-understood nutrient-sensing one, and complex 2 (mTORC2). mTORC1 reads amino acids, oxygen, and growth factors and responds by ramping up building while switching off autophagy; chronic mTORC1 activation from constant nutrient surplus is a key driver of cellular senescence and age-related disease.^[15]

The dietary lever here is protein, and the textbook explanation is that the amino acid leucine is a potent direct activator of mTORC1, tying protein intake straight to this pro-aging pathway.^[16] That explanation turns out to be too simple — as the amino-acid section below shows, restricting leucine specifically does not reproduce the benefit, and the total load matters more than the single most potent trigger. What survives is the tension covered in depth under protein: lower protein keeps mTOR quiet (good for longevity signalling), but adequate protein is needed to preserve muscle and prevent frailty (good for healthspan), and the right balance shifts with age — the same growth-versus-repair trade-off as the IGF-1 U-shape, played out on the dinner plate.

Diet, fasting, and the resilience paradox

Caloric restriction — Strong in animals, Moderate in humans (biomarker endpoints only). Reducing calorie intake without malnutrition is the most reproducible lifespan-extending intervention across species, working precisely by hitting all four hubs — turning the IIS and mTOR accelerators down and the AMPK and sirtuin brakes up.^[17]

The human test is CALERIE, which randomised 220 healthy adults without obesity to a 25% calorie-restriction target or normal eating for two years. It improved cardiometabolic markers without costing muscle, and it slowed the DunedinPACE methylation clock by roughly 2–3% — meaning the restricted group accumulated biological age about 2–3% more slowly than controls, a real but small shift. Three deflators belong with that result every time it is quoted: the methylation analysis was post hoc rather than the trial's designed test; participants achieved only about 12% restriction against the 25% target; and the effect appeared on that one pace-of-aging clock and not at all on the two static clocks tested, PhenoAge and GrimAge.^[18] It remains the cleanest human evidence that this lever does something — and it is a biomarker result, not a survival result. The clocks themselves are covered under epigenetic alterations.

Fasting-mimicking diets — Moderate. Because sustained restriction is hard and can carry costs, periodic fasting-mimicking diets (FMD) — short, structured low-calorie, low-protein cycles every few months — aim to trigger the same cellular cleanup without chronic deprivation. A secondary analysis of two randomized trials found that three monthly FMD cycles were associated with less insulin resistance and other pre-diabetes markers, lower liver fat, a younger immune-cell profile, and a roughly 2.5-year drop in a biological-age measure, independent of weight loss.^[19] Three deflators belong with that figure: the measure is not a methylation clock but a composite of seven routine blood and blood-pressure readings, and the improvement tracked changes in four of its own seven inputs; about a fifth of participants on the diet came out biologically older; and the trial diet was supplied by a company in which two of the authors hold equity. That is one small trial set measuring a biological-age estimate rather than survival. The science of intermittent fasting and time-restricted eating is the everyday version of the same idea.

The resilience paradox is the essential caveat — Moderate, and the most important result on this page. A large 2024 study put 960 genetically diverse female mice on graded caloric restriction (20% or 40% fewer calories than free feeding) or intermittent fasting (one or two fasting days a week). Eating less did extend lifespan in proportion to the degree of restriction — but genetics influenced lifespan more than the diet did, and, strikingly, the traits that best predicted a long life were holding onto body weight through stressful handling, keeping a high lymphocyte proportion, and carrying more fat in late life. The deepest restriction extended lifespan most but cost lean mass and shifted the immune repertoire in ways that could raise susceptibility to infection, and the improvements in fasting glucose and adiposity that restriction produced were not the things associated with living longer.^[20] The lesson: better metabolic numbers don't guarantee a longer life if they come at the expense of physiological reserve. A robust body needs enough muscle, lean mass, and immune capacity to survive infection and stress — which is why extreme, continuous restriction can backfire and periodic, transient stressors are the safer bet.^[21] Note the single-sex cohort: given how sharply the amino-acid results below split by sex, a female-only study is a real limit on how far this generalises.

It's not just calories: amino-acid restriction

Strong in animals; Weak in humans. The animal work is consistent and replicated across labs, but no human trial has restricted a single amino acid and measured an aging outcome.

A calorie is not merely a calorie; the composition of dietary protein independently tunes these pathways.^[22]

Branched-chain amino acids (BCAAs) — leucine, isoleucine, valine — are potent mTORC1 activators, and high circulating levels (typical of heavy animal-protein diets) track with insulin resistance and diabetes; restricting them extends healthy lifespan and reduces frailty in mice.^[23] The effect turns out to be specific rather than generic. The metabolic harm of a high-BCAA diet is carried by isoleucine and valine, and restricting leucine alone — the most potent mTORC1 activator of the three — does almost nothing, which is the clearest sign that "activates mTORC1 hardest" is not the same as "matters most."^[24] Restricting isoleucine alone extends lifespan in genetically diverse mice of both sexes, more so in males.^[25] Restricting valine alone reduces frailty, cancer and senescent-cell burden in both sexes, but extends lifespan only in males, whose median lifespan ran about 23% longer than unrestricted males — one of the sharpest sex splits in the whole dietary-restriction literature, and a warning against assuming any of these results transfer evenly.^[26]
Methionine restriction is one of the best-validated single-nutrient interventions in animals. Methionine is the precursor to the cell's universal methyl donor (S-adenosylmethionine, or SAM); when methionine is scarce, SAM falls, and a sensor that reads SAM levels releases an inhibitory brake onto mTORC1, triggering autophagy while activating fibroblast growth factor 21 — a hormone that raises energy expenditure and improves insulin sensitivity.^[27]

In practice this is much of the science under dietary patterns: plant-forward eating is naturally lower in methionine and BCAAs than a meat-heavy diet.

The drugs: caloric-restriction mimetics

Weak in humans, across the board. Every drug below has a strong mechanism, a strong animal record, and no trial showing it slows human aging as such. The GLP-1 drugs are the partial exception — they have large hard-outcome trials — but those trials tested disease, not aging. The site covers this class in depth under geroprotectors.^[28]

Rapamycin directly inhibits mTORC1 and is the most reproducible pharmacological lifespan-extender in animal models. The catch is dosing: daily high doses (as used in transplant medicine) eventually also hit mTORC2, causing insulin resistance and immune suppression, so longevity research uses low, intermittent — typically weekly — dosing to pulse autophagy while sparing mTORC2, a schedule worked out in mice before it was tried in people.^[29]^[30] The human record is thinner than the enthusiasm. PEARL, the first randomised trial of weekly rapamycin in healthy adults aged 50–85, ran 48 weeks and missed its primary endpoint — no reduction in visceral fat. It was well tolerated, and women on the higher dose gained lean mass and reported less pain, but those were secondary, subgroup-confined findings, and the trial used a compounded drug later found to deliver only about a third as much drug into the blood as generic sirolimus, rapamycin's standard pharmacy form.^[31] The strongest clinical human result for damping this pathway is older and comes from rapamycin relatives: a randomised trial gave 264 older adults six weeks of two low-dose mTOR inhibitors and found significantly fewer infections reported over the following year — the trial's central question — along with a better antibody response to influenza vaccination.^[32] That is the one place where turning the accelerator down produced a measurable clinical benefit in people, and it is a six-week course judged on one year of infections, not a longevity result. Larger institution-run trials are underway.
Metformin activates AMPK, mimicking part of the calorie-restriction signal. Diabetics on it show lower rates of several age-related diseases, and the much-discussed TAME trial was designed to test whether the benefit extends to non-diabetic older adults — using a composite of age-related diseases as its endpoint, a deliberate attempt to set a regulatory precedent for treating aging itself. It has never been funded or enrolled, so it remains a proposal rather than a study in progress (geroprotectors).^[33]
NAD⁺ precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — aim to counter the age-related NAD⁺ decline that blunts sirtuins. The first human NR trial confirmed they safely and dose-dependently raise blood NAD⁺,^[34] and a 60-day randomized trial of NMN in 80 healthy middle-aged adults reported raised blood NAD⁺, longer six-minute walking distance, and a biological-age score — one calculated from routine lab markers, not a methylation clock — that held steady while the placebo group's rose, with benefits plateauing at a moderate daily dose rather than the highest one tested.^[35] The repletion is real; durable longevity benefit in healthy people is not established.

A newer addition acts on the same axis from a different angle: GLP-1 receptor agonists — glucagon-like peptide-1 drugs such as semaglutide and tirzepatide — reduce nutrient load and have produced the strongest pharmacological signal yet on DNA-methylation aging clocks. Three caveats travel with that claim and should never be separated from it: the result is a post-hoc, exploratory analysis of a 32-week trial in a narrow special population (semaglutide n=45, placebo n=39), it remains a non-peer-reviewed preprint, and the epigenetic profiling was done by the commercial vendor whose clock is the outcome measure.^[36] Dietary caloric restriction moved these clocks first, in the general population — see GLP-1 drugs.

A practical, age-aware reading

Moderate for the direction of travel; Weak for the specifics — the age threshold below rests on one observational survey analysis.

The synthesis that falls out of all this is oscillation, not suppression: protect metabolic flexibility and the youthful feed–fast swing while preserving functional reserve.^[37] Two practical points stand out, both well covered elsewhere on the site:

Protein needs flip with age. Through midlife, a moderate, plant-forward protein intake keeps mTOR and IIS from idling high; after about 65, the priority reverses — higher protein becomes important to defend against muscle loss and frailty, even at the cost of some extra mTOR signalling. The human evidence for that flip is a single national-survey analysis built on one day of recalled diet, so treat the age threshold as directional rather than precise.^[38] The dose tables live under protein, and the training side under resistance training.
Exercise has the best combined evidence-and-safety profile of any lever here. Aerobic work — especially zone 2 training, and more so when done fasted — activates AMPK and boosts NAD⁺ synthesis, hitting the brake pathways with none of the dosing and tolerability problems that constrain the drugs.^[39]

What this does and doesn't tell you

What it tells you: nutrient sensing is the master integrative hallmark — four pathways (insulin/IGF-1, mTOR, AMPK, sirtuins) are the best candidate mechanism linking what you eat to the rate at which you age, a link established in cells and animals and inferred in humans. The accelerator-versus-brake logic explains why the best-evidenced longevity levers — eating with restraint, fasting, and exercise — plausibly work: they push the balance from growth toward repair. It also explains where the drug candidates are aimed.

What it doesn't tell you: that maximally suppressing growth signalling is the goal. The IGF-1 U-shape, the leucine result, and the resilience paradox all say otherwise — too little growth signalling, or too much weight and muscle loss, brings frailty and immune failure, and the longest-lived animals under restriction are the ones that keep their reserve. Nor does it mean any supplement or drug reliably extends human life: rapamycin's one randomised trial in healthy adults missed its primary endpoint, metformin's flagship aging trial was never funded, and the NAD⁺ case rests mostly on raising a molecule whose downstream longevity payoff isn't yet demonstrated. The durable message is the familiar one — eat with restraint, keep the feed–fast rhythm, move, and don't keep the growth machinery switched on around the clock.